SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Cybercab and robotaxi momentum is driving attention, with Teslas Texas fleet additions and upcoming launch event fueling bullish FSD, autonomy and short-squeeze speculation. Traders remain divided, with some expecting continued momentum while others view the event as a sell-the-news catalyst and question Teslas valuation, execution and robotaxi capabilities.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Anticipation of Vikings VK2735 obesity-drug maintenance-study readout is driving attention, with traders focused on whether less-frequent dosing can sustain weight loss while maintaining tolerability. Bulls view positive results as validation of the injectable program and a potential catalyst for institutional buying or short covering, while bears warn of disappointing data, a sell-the-news reaction, and future dilution.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Renewed U.S.-Iran hostilities and tensions around the Strait of Hormuz are driving the main market discussion, with traders linking the conflict to higher oil prices, inflation risks, and pressure on broader equities. The community is sharply divided, with supporters defending Trumps military stance while critics argue the war, tariffs, and resulting economic strain are hurting American consumers and the stock.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

Rising long-term Treasury yieldsdriven by persistent inflation, fiscal concerns, hawkish Federal Reserve expectations and oil-related risksare keeping TLT under pressure. Traders are divided over whether Treasury buybacks can support the long end and trigger a rebound, or merely provide temporary relief while bond-market fundamentals remain weak.

Edison International is a renewable energy company, which operates through its subsidiaries. It supplies and distributes electric power, and also invests in energy services and technologies. The company was founded on July 4, 1886, and is headquartered in Rosemead, CA.

Edison International

California lawmakers wildfire legislation failed to provide the liability protections investors expected, leaving Edison International exposed to potentially significant wildfire-related claims and prompting analyst downgrades. Traders are divided between viewing the selloff as an overreaction and buying the dividend stock, and those warning that unresolved liability, credit risk, and possible dividend pressure could drive further weakness.

Hut 8 Corp. engages in the development and operation of data centers at scale, supporting AI, high-performance computing (HPC), ASIC compute, and other energy-intensive technology applications. It operates through the following segments: Power, Digital Infrastructure, Compute, and Others. The Power segment manages the origination, development, and management of powered land and energy infrastructure. The Digital Infrastructure refers to the development, ownership, and operation of facilities designed to support next-generation, energy-intensive technology application. The Compute segment deals with operating businesses that deploy and monetize compute assets across next-generation energy-intensive technology. The Others segment offers equipment sales and repairs. The company was founded on January 27, 2023 and is headquartered in Miami, FL.

Hut 8 Corp

A quarterly earnings miss and concerns about managements execution and guidance have driven attention, with traders questioning the credibility of Hut 8s AI data-center growth plans and the timeline for Texas approvals. Bulls continue to cite its power capacity, AI infrastructure contracts, and Bitcoin exposure, but sentiment is dominated by the selloff and uncertainty over project delivery.

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Robloxs weak quarterly results, continued monetization concerns, and withdrawal of full-year guidance have driven a sharp repricing and analyst downgrades. Traders are divided between viewing the selloff as an oversold bounce opportunity, aided by short covering, and expecting further downside because of weaker growth visibility, profitability concerns, and ongoing child-safety scrutiny.

Sezzle, Inc. engages in the operation of a digital payment platform that enables bank-to-bank transfer of money between consumers and businesses. The company was founded by Charlie G. Youakim, Killian Brackey and Paul V. Paradis on January 4, 2016 and is headquartered in Minneapolis, MN.

Sezzle Inc.

A strong Q2 earnings beat and raised full-year outlook have been overshadowed by cautious second-half growth expectations, margin compression, and higher credit-loss provisions, prompting a sharp selloff. Traders are divided between viewing the reaction as an overdone valuation reset and warning that elevated multiples, insider selling, and slower growth could drive further downside.

Karman Holdings, Inc. engages in the design, testing, manufacturing, and sale of dependable missile systems. It offers Payload Protection & Deployment Systems, Aerodynamic Interstage Systems, and Propulsion Systems. The company was founded on August 20, 2020 and is headquartered in Huntington Beach, CA.

Karman Holdings Inc.

Karman Holdings Ord Shs

Karmans quarterly results and raised outlook, supported by strong defense and space demand, are driving attention. Despite the positive operating update and backlog growth, traders are debating the sharp selloff, with some attributing it to a profit-expectation miss, high valuation, and broader weakness in defense stocks.

Corvus Pharmaceuticals, Inc. engages in the development of product candidates for the treatment of cancer and immune-mediated and inflammatory diseases. Its product candidates include soquelitinib, an ITK inhibitor, ciforadenant, an adenosine A2A receptor antagonist, and mupadolimab, a B cell-activating anti-CD73 antibody. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Clinical updates and presentations for soquelitinib in atopic dermatitis and PTCL are driving attention, with traders focused on efficacy, durability, and upcoming development milestones. Bullish participants view the early data as potentially transformative, while skeptics point to the small Phase 1 evidence base, delayed readouts, and lack of near-term commercial catalysts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Speculation about a potential Big Pharma acquisition or partnership before Structure Therapeutics begins Phase 3 is the dominant discussion, alongside anticipation of upcoming amylin and ACCESS follow-up data. Traders are divided: some view the oral GLP-1 pipeline and recent management activity as deal catalysts, while others point to uncertain tolerability, liver-safety risks and the absence of a confirmed transaction.

Can CagriSema Help Novo Nordisk Close the Gap With LLY in Obesity?

NVO's CagriSema is under U.S. regulatory review for obesity, with continued clinical progression to expand use amid increasing competition from LLY.

NVO vs. GPCR: Which Obesity Stock Is the Better Buy Right Now?

Novo Nordisk and Structure Therapeutics are taking different paths in the obesity market, from a global GLP-1 leader to a clinical-stage challenger with oral therapies.

Can Awiqli Help Novo Nordisk Build a New Growth Engine Beyond GLP-1s?

NVO's U.S. launch of Awiqli introduces the first once-weekly basal insulin, potentially giving the company a new growth opportunity beyond its pressured GLP-1 franchise.

How Does LLY's Q2 GLP-1 Portfolio Performance Stack Up Against NVO's?

Eli Lilly's GLP-1 portfolio outpaces its rival in Q2, while Foundayo gains momentum and can challenge Wegovy's early oral obesity lead.

LLY Up Around 6% Post Robust Q2 Results: Buy, Sell or Hold the Stock?

Lilly's strong Q2, GLP-1 momentum and broad pipeline support growth, but valuation and rising competition remain key risks.

Can Novo Nordisk's GLP-1 Pill Momentum Offset LLY's Growing Edge?

NVO's GLP-1 pills offer fresh momentum, but Eli Lilly's fast-growing injectable and oral therapies threaten to widen the competitive gap.

LLY's Foundayo Posts $98M in Q2 Sales: What's Next for the Oral GLP-1?

Lilly's Foundayo records $98M in Q2 sales, while rising prescriptions, broader access and global expansion set the stage for H2 growth

Novo Nordisk Dips 4% in a Month: How Should Investors Play the Stock?

NVO faces near-term pressure from flat Wegovy sales, pricing challenges and pipeline setbacks, but its broad cardiometabolic pipeline offers long-term potential.

Novo Nordisk Before Q2 Earnings: How Should Investors Play the Stock?

NVO heads into Q2 earnings under pressure as slowing injectable GLP-1 momentum, pricing headwinds and fierce competition cloud the near-term outlook.

 VKTX Stock Lags GLP-1 Peers In July — But Viking CEO Says Its Obesity Drug Could Offer What Rivals Can’t 

Equity

Viking expects oral VK2735 Phase 3 studies to begin in Q4 and believes the pill could become the first oral dual GLP-1 agonist to reach the market.

Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its pipeline includes Aleniglipron GSBR-1290, ACCG-2671, GIPR, GCGR, ANPA-0073, and LTSE-2578. The company was founded by Raymond C. Stevens in 2016 and is headquartered in South San Francisco, CA.

Structure Therapeutics Inc - ADR

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$45.91
Prev Close	$47.37
Open	$47.08
Dividend Yield	0.00%
50-Day Moving Average	$50.62
Beta	0.85
Avg. Volume	618,752.03
PE Ratio	-15.38

52-Week High	$94.90
52-Week Low	$18.49
Market Capitalization	$3.38B
EPS (Annual)	-$2.39
Price to Book	2.49
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info